Cowen And Company, LLC Mirati Therapeutics, Inc. Transaction History

Cowen And Company, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$41.99 - $62.38 $5.2 Million - $7.72 Million	123,783 New	123,783 $7.27 Million
Q2 2022 Aug 05, 2022	SELL	$39.16 - $88.71 $97,234 - $220,266	-2,483 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $240,728 - $479,329	-3,175 Reduced 56.12%	2,483 $204,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $746,912 - $1.08 Million	5,658 New	5,658 $830,000
Q2 2021 Aug 13, 2021	SELL	$144.0 - $179.73 $2.93 Million - $3.65 Million	-20,324 Closed	0 $0
Q1 2021 May 04, 2021	BUY	$158.92 - $221.61 $2.58 Million - $3.6 Million	16,223 Added 395.59%	20,324 $3.48 Million
Q3 2020 Nov 03, 2020	SELL	$113.26 - $167.27 $1.79 Million - $2.65 Million	-15,837 Reduced 79.43%	4,101 $681,000
Q4 2019 Feb 11, 2020	BUY	$70.76 - $128.86 $1.41 Million - $2.57 Million	19,938 New	19,938 $2.57 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.